Evidence map›Paper›PMID 28835386›Full record

ArticleMolecular cancer therapeutics2017

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03894215 (A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034), which is not on this map. Cited by 1,425 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,425citing papers in PubMed, 6 pooled it
103.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03894215 phase2terminatednot on this mapstarted 2019, after this paper: background citation

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

TypeinterventionalSponsorAgenus Inc.Ran2019 to 2025Enrolled211ConditionsCervical CancerArmsAGEN2034, AGEN1884
3 · Its place in the literature

Who cites it

1,425 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,359 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

1,365 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Aaron M GoodmanDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California. a1goodman@ucsd.edu.
Shumei KatoDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Lyudmila BazhenovaDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Sandip P PatelDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Garrett M FramptonFoundation Medicine, Cambridge, Massachusetts.
Vincent MillerFoundation Medicine, Cambridge, Massachusetts.
Philip J StephensFoundation Medicine, Cambridge, Massachusetts.
Gregory A DanielsDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Razelle KurzrockDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
University of California San Diego · USGlobalFoundries (United States) · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (

Indexed as

AgedAnimalsAntibodies, MonoclonalB7-H1 AntigenCarcinoma, Non-Small-Cell LungCell Line, TumorCTLA-4 AntigenDisease-Free SurvivalFemaleHumansImmunotherapyMaleMelanomaMiceMiddle AgedMutationAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID28835386
PMCPMC5670009
OpenAlexW2747774814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.